Skip to content

Clinical study on the imaging of pancreatic cancer using 68Ga-labeled Claudin 18.2 imaging agent combined with PET/CT

Clinical study on the imaging of pancreatic cancer using 68Ga-labeled Claudin 18.2 imaging agent combined with PET/CT

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113686
Enrollment
Unknown
Registered
2025-12-02
Start date
2025-12-02
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Test group:68Ga-NODAGA-SNA014 and 18F-FDG PET-CT imaging

Sponsors

Tianjin Medical University Cancer Institute and Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18 to 75 years old (inclusive); 2. Individuals with behavioral capacity who voluntarily participate in this clinical study and sign the Informed Consent Form (ICF); 3. Confirmed as pancreatic cancer through histopathology or cytology; or suspected of having pancreatic cancer based on imaging or clinical findings, with plans to perform tumor resection or tissue biopsy within 60 days after enrollment, and the patient must agree to provide sufficient and appropriate tumor tissue samples (formalin-fixed, paraffin-embedded samples) for pathological testing by the research center after surgery; 4. The patient has not received the following treatments for the tumor: radiotherapy (including brachytherapy), systemic anti-tumor drugs (chemotherapy, small molecule targeted drugs, monoclonal antibody drugs, etc.), or other experimental treatments in clinical research.

Exclusion criteria

Exclusion criteria: 1. Incorporate other patients with clearly diagnosed malignant tumors; 2. Individuals with uncontrolled severe infections, or those accompanied by other serious illnesses; 3. Patients with an expected survival period of <=3 months; 4. Pregnant or lactating patients, as well as childbearing-age patients who refuse to take appropriate contraceptive measures during the trial; 5. Patients whom the researchers judged as unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Medication Safety;PET Imaging Characteristics;

Secondary

MeasureTime frame
The correlation between PET imaging and Claudin 18.2 expression levels as measured by immunohistochemistry (IHC);Diagnostic Efficacy;

Countries

China

Contacts

Public ContactDai Dong

Tianjin Medical University Cancer Institute and Hospital

xiandao5502@163.com+86 186 2200 0577

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026